Bladder cancer and prostate cancer are the most common malignant tumors of the urinary system. Researchers have been working hard to reveal different types and properties of tumor antigens in bladder cancer and prostate cancer, and to study the immune surveillance of tumors, including anti-tumor immune responses, tumor immune escape mechanisms, immunodiagnosis, immune prevention, and immunotherapy. The immune system of the body has the function of immune surveillance. When tumor cells invade, the immune system can recognize and eliminate them based on the tumor antigens expressed on their surfaces. However, in some cases, tumor cells can evade the body's immune surveillance through various mechanisms, proliferate malignantly, and form tumors.
This Research Topic focuses on the research on the occurrence and development of bladder cancer and prostate cancer by Immune transcriptomics and immune metabolomics and explores new cancer intervention methods. We welcome manuscripts that deal with the following subtopics:
• Make full use of bioinformatics, biochips, high-throughput screening, and other technologies to carry out a large-scale research on the molecular mechanism of bladder cancer and prostate cancer immune response, to discover the functions of new immune-related molecules, and to provide a comprehensive system understanding on the immune system and related immune responses.
• The relationship between bladder cancer and prostate cancer antigens, the immune function of the body, and the occurrence, development, and outcome of bladder cancer and prostate cancer.
• The mechanism of the body's immune response to bladder cancer and prostate cancer and the immune mechanism of bladder cancer and prostate cancer cells’ escape.
• The bladder cancer and prostate cancer immunodiagnosis and immune prevention.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Bladder cancer and prostate cancer are the most common malignant tumors of the urinary system. Researchers have been working hard to reveal different types and properties of tumor antigens in bladder cancer and prostate cancer, and to study the immune surveillance of tumors, including anti-tumor immune responses, tumor immune escape mechanisms, immunodiagnosis, immune prevention, and immunotherapy. The immune system of the body has the function of immune surveillance. When tumor cells invade, the immune system can recognize and eliminate them based on the tumor antigens expressed on their surfaces. However, in some cases, tumor cells can evade the body's immune surveillance through various mechanisms, proliferate malignantly, and form tumors.
This Research Topic focuses on the research on the occurrence and development of bladder cancer and prostate cancer by Immune transcriptomics and immune metabolomics and explores new cancer intervention methods. We welcome manuscripts that deal with the following subtopics:
• Make full use of bioinformatics, biochips, high-throughput screening, and other technologies to carry out a large-scale research on the molecular mechanism of bladder cancer and prostate cancer immune response, to discover the functions of new immune-related molecules, and to provide a comprehensive system understanding on the immune system and related immune responses.
• The relationship between bladder cancer and prostate cancer antigens, the immune function of the body, and the occurrence, development, and outcome of bladder cancer and prostate cancer.
• The mechanism of the body's immune response to bladder cancer and prostate cancer and the immune mechanism of bladder cancer and prostate cancer cells’ escape.
• The bladder cancer and prostate cancer immunodiagnosis and immune prevention.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.